IR@PKUHSC  > 北京大学精神卫生研究所
Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys
Kessler, R. C.1; Sampson, N. A.1; Berglund, P.2; Gruber, M. J.1; Al-Hamzawi, A.3; Andrade, L.4; Bunting, B.5; Demyttenaere, K.6; Florescu, S.7; de Girolamo, G.8; Gureje, O.9; He, Y.10; Hu, C.11,12; Huang, Y.13; Karam, E.14,15,16; Kovess-Masfety, V.17; Lee, S.18; Levinson, D.19; Medina Mora, M. E.20; Moskalewicz, J.21; Nakamura, Y.22; Navarro-Mateu, F.23; Browne, M. A. Oakley24; Piazza, M.25; Posada-Villa, J.26; Slade, T.27; ten Have, M.28; Torres, Y.29; Vilagut, G.30; Xavier, M.31,32; Zarkov, Z.33; Shahly, V.1; Wilcox, M. A.34
关键词Anxious Depression Comorbidity Epidemiology
收录类别SCI ; SSCI
WOS标题词Science & Technology

Background. To examine cross-national patterns and correlates of lifetime and 12-month comorbid DSM-IV anxiety disorders among people with lifetime and 12-month DSM-IV major depressive disorder (MDD).

Method. Nationally or regionally representative epidemiological interviews were administered to 74045 adults in 27 surveys across 24 countries in the WHO World Mental Health (WMH) Surveys. DSM-IV MDD, a wide range of comorbid DSM-IV anxiety disorders, and a number of correlates were assessed with the WHO Composite International Diagnostic Interview (CIDI).

Results. 45.7% of respondents with lifetime MDD (32.0-46.5% inter-quartile range (IQR) across surveys) had one of more lifetime anxiety disorders. A slightly higher proportion of respondents with 12-month MDD had lifetime anxiety disorders (51.7%, 37.8-54.0% IQR) and only slightly lower proportions of respondents with 12-month MDD had 12-month anxiety disorders (41.6%, 29.9-47.2% IQR). Two-thirds (68%) of respondents with lifetime comorbid anxiety disorders and MDD reported an earlier age-of-onset (AOO) of their first anxiety disorder than their MDD, while 13.5% reported an earlier AOO of MDD and the remaining 18.5% reported the same AOO of both disorders. Women and previously married people had consistently elevated rates of lifetime and 12-month MDD as well as comorbid anxiety disorders. Consistently higher proportions of respondents with 12-month anxious than non-anxious MDD reported severe role impairment (64.4 v. 46.0%; chi(2)(1)=187.0, p<0.001) and suicide ideation (19.5 v. 8.9%;chi(2)(1)=71.6, p<0.001). Significantly more respondents with 12-month anxious than non-anxious MDD received treatment for their depression in the 12 months before interview, but this difference was more pronounced in high-income countries (68.8 v. 45.4%; chi(2)(1)=108.8, p<0.001) than low/middle-income countries (30.3 v. 20.6%; chi(2)(1)=11.7, p<0.001).

Conclusions. Patterns and correlates of comorbid DSM-IV anxiety disorders among people with DSM-IV MDD are similar across WMH countries. The narrow IQR of the proportion of respondents with temporally prior AOO of anxiety disorders than comorbid MDD (69.6-74.7%) is especially noteworthy. However, the fact that these proportions are not higher among respondents with 12-month than lifetime comorbidity means that temporal priority between lifetime anxiety disorders and MDD is not related to MDD persistence among people with anxious MDD. This, in turn, raises complex questions about the relative importance of temporally primary anxiety disorders as risk markers v. causal risk factors for subsequent MDD onset and persistence, including the possibility that anxiety disorders might primarily be risk markers for MDD onset and causal risk factors for MDD persistence.

项目编号R01MH059575 ; U01-MH60220 ; 044708 ; R01MH070884 ; R13-MH066849 ; R01-MH069864 ; R01 DA016558 ; FIRCA R03-TW006481 ; 03/00204-3 ; QLG5-1999-01042 ; SANCO 2004123 ; FIS 00/0028 ; SAF 2000-158-CE ; CIBER CB06/02/0046 ; RETICS RD06/0011 REM-TAP ; H13-SHOGAI-023 ; H14TOKUBETSU-026 ; H16-KOKORO-013 ; INPRFMDIES 4280 ; CONACyT-G30544-H
资助机构PanAmerican Health Organization (PAHO) ; New Zealand Ministry of Health ; Alcohol Advisory Council ; Health Research Council ; WHO (Geneva) ; WHO (Nigeria) ; Federal Ministry of Health, Abuja, Nigeria ; Ministry of Public Health (former Ministry of Health) ; EAA/Norwegian Financial Mechanisms as well as by the Polish Ministry of Health ; US National Institute of Mental Health ; South African Department of Health ; University of Michigan ; National Institute of Mental Health (NIMH) ; National Institute of Drug Abuse (NIDA) ; Substance Abuse and Mental Health Services Administration (SAMHSA) ; Robert Wood Johnson Foundation (RWJF) ; John W. Alden Trust ; United States National Institute of Mental Health ; John D. and Catherine T. MacArthur Foundation ; Pfizer Foundation ; US Public Health Service ; Fogarty International Center ; Pan American Health Organization ; Eli Lilly &amp ; Company Foundation ; Ortho-McNeil Pharmaceutical, Inc. ; GlaxoSmithKline ; Bristol-Myers Squibb and Shire ; State of Sao Paulo Research Foundation (FAPESP) Thematic Project Grant ; Ministry of Health ; National Center for Public Health Protection ; Shenzhen Bureau of Health ; Shenzhen Bureau of Science, Technology, and Information ; Ministry of Social Protection ; European Commission ; Piedmont Region (Italy), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain ; Ministerio de Ciencia y Tecnologia, Spain ; Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III ; WHO (India) ; Iraqi IMHS team ; Japanese and European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF) ; Israel National Institute for Health Policy and Health Services Research ; National Insurance Institute of Israel ; Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labour and Welfare ; Lebanese Ministry of Public Health ; WHO (Lebanon) ; Fogarty International ; Act for Lebanon ; anonymous private donations to IDRAAC ; Janssen Cilag ; Eli Lilly ; Roche ; Novartis ; National Institute of Psychiatry Ramon de la Fuente ; National Council on Science and Technology
被引频次:48[WOS]   [WOS记录]     [WOS相关记录]
作者单位1.Netherlands Inst Mental Hlth & Addict, Utrecht, Netherlands
2.CES Univ, Ctr Excellence Res Mental Hlth, Medellin, Colombia
3.NCPHA, Dept Mental Hlth, Sofia, Bulgaria
4.Janssen Pharmaceut Res & Dev, Titusville, NJ USA
5.Al Qadisiya Univ, Coll Med, Diwania Governorate, Iraq
6.Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil
7.Univ Ulster, Sch Psychol, Londonberry, Ireland
8.Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA
9.Univ Michigan, Inst Social Res, Ann Arbor, MI USA
10.Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Psychiat, Leuven, Belgium
11.Natl Sch Publ Hlth Management & Profess Dev, Bucharest, Romania
12.IRCCS St John God Clin Res Ctr, Unit Epidemiol & Evaluat Psychiat, Brescia, Italy
13.Univ Ibadan, Dept Psychiat, Ctr Res & Training Mental Hlth Neurosci Drug & Al, Ibadan, Nigeria
14.Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, Shanghai 200030, Peoples R China
15.Shenzhen Inst Mental Hlth, Shenzhen, Guangdong, Peoples R China
16.Shenzhen Kanging Hosp, Shenzhen, Guangdong, Peoples R China
17.Peking Univ, Inst Mental Hlth, Beijing 100871, Peoples R China
18.Balamand Univ, Fac Med, Dept Psychiat & Clin Psychol, Beirut, Lebanon
19.St George Hosp Univ, Med Ctr, Dept Psychiat & Clin Psychol, Beirut, Lebanon
20.IDRAAC, Beirut, Lebanon
21.Paris Descartes Univ, EHESP, EA 4057, Paris, France
22.Chinese Univ Hong Kong, Dept Psychiat, Shatin, Hong Kong, Peoples R China
23.Minist Hlth Israel, Mental Hlth Serv, Jerusalem, Israel
24.Ramond e Fuente Muniz Natl Inst Psychiat, Mexico City, DF, Mexico
25.Inst Psychiat & Neurol, Warsaw, Poland
26.Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi, Japan
27.CIBERESP Nodo, IMIB Arrixaca, Serv Murciano Salud, UDIF SM, Murcia, Spain
28.Natl Inst Hlth, Lima, Peru
29.Univ Colegio Mayor Cundinamarca, Bogota, Colombia
30.Univ Tasmania, Sch Med, Dept Psychiat, Hobart, Tas 7001, Australia
31.Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia
32.IMIM Inst Hosp Mar Invest Med, Hlth Serv Res Unit, Edifici PRBB, Barcelona 08003, Spain
33.Univ Nova Lisboa, Dept Mental Hlth CEDOC, P-1200 Lisbon, Portugal
34.Univ Nova Lisboa, Fac Ciencias Med, P-1200 Lisbon, Portugal
GB/T 7714
Kessler, R. C.,Sampson, N. A.,Berglund, P.,et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys[J]. EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES,2015,24(3):210-226.
APA Kessler, R. C..,Sampson, N. A..,Berglund, P..,Gruber, M. J..,Al-Hamzawi, A..,...&Wilcox, M. A..(2015).Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys.EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES,24(3),210-226.
MLA Kessler, R. C.,et al."Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys".EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES 24.3(2015):210-226.
[Kessler, R. C.]的文章
[Sampson, N. A.]的文章
[Berglund, P.]的文章
[Kessler, R. C.]的文章
[Sampson, N. A.]的文章
[Berglund, P.]的文章
[Kessler, R. C.]的文章
[Sampson, N. A.]的文章
[Berglund, P.]的文章
所有评论 (0)